M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 14.64 PLN -0.41% Market Closed
Updated: May 19, 2024

Relative Value

The Relative Value of one MOC stock under the Base Case scenario is hidden PLN. Compared to the current market price of 14.64 PLN, Molecure SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOC Relative Value
HIDDEN
Unlock
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
28
vs Industry
2
Median 3Y
179.9
Median 5Y
0
Industry
2.5
Forward
162.7
vs History
vs Industry
Median 3Y
-19
Median 5Y
0
Industry
23.5
Forward
-14.5
vs History
vs Industry
Median 3Y
-35.3
Median 5Y
0
Industry
17.4
vs History
vs Industry
Median 3Y
-34.3
Median 5Y
0
Industry
24.3
vs History
55
vs Industry
50
Median 3Y
2.4
Median 5Y
1.6
Industry
2.1
vs History
31
vs Industry
3
Median 3Y
122.8
Median 5Y
0
Industry
2.6
Forward
108.8
vs History
vs Industry
0
Median 3Y
-390.6
Median 5Y
0
Industry
5.3
vs History
vs Industry
Median 3Y
-13.9
Median 5Y
0
Industry
13.7
Forward
-8.4
vs History
vs Industry
Median 3Y
-12.9
Median 5Y
0
Industry
17.4
Forward
-7.7
vs History
vs Industry
Median 3Y
-25.4
Median 5Y
0
Industry
16.2
vs History
vs Industry
Median 3Y
-22.5
Median 5Y
0
Industry
18.6
vs History
57
vs Industry
38
Median 3Y
3.1
Median 5Y
2.3
Industry
1.9

Multiples Across Competitors

MOC Competitors Multiples
Molecure SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Molecure SA
WSE:MOC
246.5m PLN 179.2 -14.2 -8.2 -7.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
731.8B USD 20.4 119.2 58.4 66.4
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 16.5 45.1 33.6 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.2B USD 4.3 9.7 11.9 15.6
US
Merck & Co Inc
NYSE:MRK
332.3B USD 5.4 144.1 35.9 58.5
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP 5 37.6 174.5 278.3
CH
Roche Holding AG
SIX:ROG
189B CHF 3.2 16.4 9.3 11
CH
Novartis AG
SIX:NOVN
182.7B CHF 3.4 11.5 8.7 12.7
US
Pfizer Inc
NYSE:PFE
162.3B USD 2.9 -525.3 12.7 20.6
P/E Multiple
Earnings Growth
PL
M
Molecure SA
WSE:MOC
Average P/E: 54.8
Negative Multiple: -14.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.2
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.7
-21%
US
Merck & Co Inc
NYSE:MRK
144.1
7 453%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -525.3
680%
EV/EBITDA Multiple
EBITDA Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBITDA: 465.7
Negative Multiple: -8.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A
US
Eli Lilly and Co
NYSE:LLY
58.4
140%
DK
Novo Nordisk A/S
CSE:NOVO B
33.6
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
US
Johnson & Johnson
NYSE:JNJ
11.9
12%
US
Merck & Co Inc
NYSE:MRK
35.9
343%
UK
AstraZeneca PLC
LSE:AZN
174.5
55%
CH
Roche Holding AG
SIX:ROG
9.3
18%
CH
Novartis AG
SIX:NOVN
8.7
3%
US
Pfizer Inc
NYSE:PFE
12.7
23%
EV/EBIT Multiple
EBIT Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBIT: 2 022.5
Negative Multiple: -7.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A
US
Eli Lilly and Co
NYSE:LLY
66.4
163%
DK
Novo Nordisk A/S
CSE:NOVO B
36.9
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
US
Johnson & Johnson
NYSE:JNJ
15.6
29%
US
Merck & Co Inc
NYSE:MRK
58.5
707%
UK
AstraZeneca PLC
LSE:AZN
278.3
141%
CH
Roche Holding AG
SIX:ROG
11
23%
CH
Novartis AG
SIX:NOVN
12.7
49%
US
Pfizer Inc
NYSE:PFE
20.6
59%

See Also

Discover More